RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Utilizzo di cellule staminali neurali tumorali come modello di studio in vitro e in vivo di glioblastoma adulto umano
• 2 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 3 - Isolamento e caratterizzazione molecolare e funzionale delle cellule staminali leucemiche (LSCs) per lo sviluppo di nuove strategie terapeutiche.
• 4 - Ruolo delle cellule staminali prostatiche e della stimolazione ipossica nella progressione tumorale.
• 5 - COMPLICANZE OSTETRICHE DA ANTICORPI ANTI-FOSFOLIPIDI: meccanismi patogenetici molecolari quali nuovi target terapeutici e marcatori prognostici.
• 6 - Nuove conoscenze fisiopatologiche per nuove prospettive terapeutiche del colangiocarcinoma
• 7 - Apoptosi e terapia del cancro: caratterizzazione di nuovi meccanismi e nuove molecole modulatrici dell'apoptosi
• 8 - Ruolo dell'angiogenesi e dell'infiammazione nella progressione tumorale
• 9 - Le interazioni tra tumore ed ospite: meccanismi di immunosoppressione/tolleranza e di attivazione della risposta immune
• 10 - I membri della famiglia del TNF nella modulazione del differenziamento cellulare e dell'attività antitumorale

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • CHIRURGIA PLASTICA
  • MALATTIE APPARATO LOCOMOTORE
  • PEDIATRIA GENERALE E SPECIALISTICA
• Area scientifico disciplinare: Scienze biologiche

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1.Dominici M et al. Bone marrow mesenchymal cells: biological properties and clinical applications. J of Biol Regulators and Homeostatic Agents.2001;15:28-37.
2.Druker BJ et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med.2001; 344:1038-42.
3.Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Can.2001;1:118-29.
4.Syme RM et al Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. J Hematother Stem Cell Res.2001;10:621-30.
5.Sadelain M et Al. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer.2003;3:35-45.
6.Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res.
2001;7:95-106.
7.Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol.2002;17:623-37.
8.Ashkenazi A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest.1999; 104: 155-62.
9.Keane MM et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res.1999; 59:734-41.
10.Morgan M et al. Chemosensitization of T-47D breast carcinoma cells to TRAIL and Fas receptor-induced killing. Anticancer Res.2002; 22:673-6.
11.Lin T et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene.2002; 21: 8020-8.
12.Yamashita Y et al. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther.2002;13:275-86.
13.Kagawa S et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res.2001;61:3330-8.
14.Evdokiou A et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to
Apo2L/TRAIL-induced apoptosis. Int J Cancer.2002;99:491-504.
15. Dominici M et al. Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells, MSCs: the International Society for Cellular Therapy Position Statement. Cytotherapy. 2006 (in press)
16.Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-28.
17.Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000;109:235-42.
18.Castro-Malaspina H et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their
progeny. Blood.1980;56:289-301.
19. Friedenstein AJ et al. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet.1987; 20: 263-72.
20. Dominici M et al. Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci U S A.2004;101:11761-6.
21. Pimanda JE et al. Transcriptional link between blood and bone: the stem cell leukemia gene and its +19 stem cell enhancer are active in bone cells. Mol Cell Biol.2006;26:2615-25.
22.Mihara K et al. Development and functional characterization of human bone marrow mesenchymal cell immortalized by enforced expression of telomerase.Br J Haematol.2003;120:846-9.
23.Pereira RF et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A.1995;92:4857-61.
24.Gao J et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs.2001;169:12-20.
25.Devine SV et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non-human primates.Blood.2003;101:2999-3001.
26.Thalmeier K et al. Mesenchymal differentiation and organ distribution of established human stromal cell lines in NOD/SCID mice. Acta Haematol.2001;105:159-65.
27.Lazarus HM et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells
(mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant.1995;16:557-64.
28.Koc ON et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).Bone Marrow Transplant.2002;30:215-22.
29.Horwitz EM et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A.2002;99:8932-7.
30. Le Blanc K et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363:1439–41.
31.Marx JC et al. High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum Gene Ther.1999;10:1163-73.
32.Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol.2000;28:382-90.
33.Chuah MK et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A.Hum Gene Ther.1998;9:353-65.
34.Hurwitz DR et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther.1997;8:137-56.
35. Studeny M et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-g delivery into tumors. Cancer Res.2002;62:3603–8.
36. Studeny M et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst.2004;96:1593–603.
37. Komarova S et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther.2006;5:755-65.
38.Ronnov-Jessen L et al. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev.1996;76:69-125.
39.Reddi AH et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res.2003;18: 190-4.
40.Hanahan D, Folkman J. Patters and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell.1996; 86:353-64.
41.Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer.2002;2:442-54.
42.Shekhar MP et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation : implications for tumor development and progression. Cancer Res.2001;61:1320-6.
43.Petersen OW et al. Epithelial to mesenchymal transition in human breast cancer can provide a non malignant stroma. Am J Pathol.2003;162:391-402.
44.Devine MJ et al. Transplanted bone marrow cells localize to fracture callus in a mouse model. J Orthop Res.2002;20:1232-9.
45.Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-2.
46.Lutzko C et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood.1999;93:1895-905.
47.Lam AC et al. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used and engraftment in NOD/SCID mice. Transfusion. 2001;41:1567-76
48.Buchler T et al. Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine
combinations. Vaccine. 2003;21:877-82.
49. Anselme K et al. In Vitro Control of Human Bone Marrow Stromal Cells for Bone Tissue Engineering. Tissue Eng. 2002;8:941-953.

Parole Chiave

TERAPIA GENICA, CANCRO, CELLULE MESENCHIMALI STAMINALI, METASTASI OSSEE, RIGENERAZIONE OSSEA, MICROCHIRURGIA